Home

The Korea Herald

Latest news

Most Popular

  1. 1

    IMF lowers Korea's 2025 growth outlook to 2%

    IMF lowers Korea's 2025 growth outlook to 2%
  2. 2

    Labor Ministry dismisses Hanni harassment case

    Labor Ministry dismisses Hanni harassment case
  3. 3

    North Korean troops fighting alongside Russia, NIS confirms

    North Korean troops fighting alongside Russia, NIS confirms
  4. 4

    Reality show 'I Live Alone' disciplined for 'glorifying' alcohol consumption

    Reality show 'I Live Alone' disciplined for 'glorifying' alcohol consumption
  5. 5

    [Herald Interview] How Gopizza got big in India

    [Herald Interview] How Gopizza got big in India
  1. 6

    Japan to hold 1st memorial for Korean forced labor victims at Sado mine

    Japan to hold 1st memorial for Korean forced labor victims at Sado mine
  2. 7

    Yoon focuses on expanding global solidarity against NK-Russia military ties at APEC, G20 summits

    Yoon focuses on expanding global solidarity against NK-Russia military ties at APEC, G20 summits
  3. 8

    [KH Explains] Dissecting Hyundai Motor's lobbying in US

    [KH Explains] Dissecting Hyundai Motor's lobbying in US
  4. 9

    [Kim Seong-kon] Farewell to the vanishing John Wayne era

    [Kim Seong-kon] Farewell to the vanishing John Wayne era
  5. 10

    [Graphic News] 70% of S. Koreans believe couples can live together without tying the knot: survey

    [Graphic News] 70% of S. Koreans believe couples can live together without tying the knot: survey
소아쌤

Samsung Bioepis seeks approval for Humira biosimilar in Korea

By 이지윤

Published : Sept. 26, 2016 - 15:02

    • Link copied

[THE INVESTOR] Samsung Bioepis is seeking regulatory approval to sell its biosimilar drug referencing AbbVie’s top-selling rheumatoid drug Humira in South Korea.

According to industry sources on Sept. 26, the biopharma development unit of Samsung Group has recently submitted its application to the Korean authorities for the sales approval of its Humira biosimilar, called SB5.

Sources said the final approval could be granted in the first half of next year. 


A researcher works at a lab of Samsung Bioepis. A researcher works at a lab of Samsung Bioepis.


Humira, together with Enbrel and Remicade, are considered the top-selling biotech drugs that block chemicals linked to inflammation.

Samsung Bioepis is already selling its own biosimilar versions of Enbrel and Remicade in South Korea and Europe.

Adding to the three drugs, the company is also waiting for the approval for its SB3, a biosimilar for Roche’s breast cancer drug Herceptin, in South Korea.

By Lee Ji-yoon (jylee@heraldcorp.com)

More from Headlines